Second-Line ITP Treatments: Weighing Side Effects, Long-Term Risks, and Patient Factors

Immune thrombocytopenia treatments require carefully weighing short-term side effects against long-term risks to achieve stable platelet counts for this chronic blood disorder, as everydayhealth.com reported.

Second-Line Therapies Balance Efficacy Against Distinct Risks

  • Second-Line Shifts: Patients typically move past initial steroid treatments to targeted medications or procedures when managing persistent low platelet counts.
  • Balancing Efficacy and Risk: Each therapy carries distinct trade-offs, ranging from blood clot vulnerabilities with bone-marrow stimulants to lifelong infection risks following a splenectomy.
  • Individualized Triage: Treatment selection depends heavily on personal health history, cardiovascular factors, liver function, and lifestyle goals.

Weighing Second-Line Therapy Options

Life with immune thrombocytopenia (ITP) typically means moving past initial steroid treatments to second-line therapies to achieve stable levels of platelets — blood cells important for clotting. When choosing a second-line treatment for this chronic blood disorder, it’s important to carefully weigh each option’s potential short-term side effects and long-term risks — and determine what you’re willing to live with, everydayhealth.com reported.

Some patients see the potential side effects of therapies as a really big deal, according to James Bussel, MD, a hematologist at Weill Cornell Medicine in New York City. “Other patients recognize [them] as being relatively infrequent and not likely to be serious or lasting,” he told everydayhealth.com. “And they say, ‘Hey, this sounds like the best treatment efficacy-wise. Let’s give it a try.'”

Thrombopoietin receptor agonists — the once-daily oral pills eltrombopag (Promacta) and avatrombopag (Doptelet), and the weekly subcutaneous injection romiplostim (Nplate) — work by stimulating platelet production in bone marrow, essentially mimicking the role of the hormone thrombopoietin. TPO-RAs require “ongoing therapy” to affect platelet levels and “have a relatively good safety profile,” said Cindy Neunert, MD, a hematologist at Columbia University Irving Medical Center, as reported by everydayhealth.com and health.yahoo.com.

Side effects of TPO-RAs are typically mild and commonly include headache, fatigue, pain in the joints, muscles, or belly, nausea, diarrhea, dizziness, and cold-like symptoms.

Increased blood clots are the main long-term safety concern with TPO-RAs, especially for people over 60 and those with known risk factors, such as a clotting disorder. Eltrombopag carries an additional warning for serious liver damage, requiring regular liver tests while on the medication, everydayhealth.com noted.

Second-Line ITP Treatments: Weighing Side Effects, Long-Term Risks, and Patient Factors
Photo: health.yahoo.com
Treatment Class Mechanism of Action Common Side Effects Primary Long-Term Risk
TPO-RAs Stimulates platelet production in bone marrow Headache, fatigue, joint/belly pain Blood clots, liver monitoring (eltrombopag)
Rituximab Depletes CD20-expressing B-cells Infusion reactions, fever, chills Immunosuppression, infection risk
SYK Inhibitors Blocks signaling inside macrophages Diarrhea, nausea, high blood pressure Liver function changes, low white cells
Splenectomy Surgical removal of platelet-destroying spleen Post-surgery bleeding, acute infection Lifelong infection and thrombosis risk

Rituximab Depletes B-Cells Causing Prolonged Immunosuppression

Usually given as a single course of four weekly intravenous infusions, rituximab attaches to the CD20 protein on B-cells, signaling the immune system to destroy them. Depleting B-cells helps remove the body’s source of platelet-targeting antibodies, everydayhealth.com outlined. Providers may administer steroids before each infusion to prevent short-term infusion reactions like rash, hives, fever, chills, headache, flushing, and dizziness.

Because the drug depletes B-cells, “rituximab will definitely lead to immunosuppression,” Neunert said, noting that depletion can last for many months and increase the risk of serious infections. Spleen tyrosine kinase inhibitors like fostamatinib (Tavalisse) block a key signaling enzyme inside macrophages, the immune cells that destroy antibody-tagged platelets.

Fostamatinib can cause diarrhea, high blood pressure, nausea, respiratory infections, dizziness, rash, and belly pain, while carrying the lowest clot risk of any second-line ITP treatment, according to health.yahoo.com.

Splenectomy, or the surgical removal of the spleen, was historically the primary second-line treatment of choice because the organ serves as a site of platelet destruction and antibody production. While often effective, splenectomy is now generally suggested only after other therapies have failed or if patients want to avoid long-term medication, largely because the treatment and its risks are permanent, everydayhealth.com reported.

Neunert said that splenectomy carries “a lifelong risk of infection and a lifelong risk of thrombosis [blood clotting],” adding that approximately 20 percent of people do not achieve stable platelet levels after surgery, and about 20 to 30 percent who do respond later experience a relapse.

Patient Factors Guide Second-Line Treatment Safety Decisions

Knowing the risks and safety profile of each treatment option helps guide clinical decisions, but providers must evaluate specific health histories. Critical factors include patient age, cardiovascular health, liver health, history of infections such as hepatitis B, cancer history, concurrent medications, lifestyle routines, and pregnancy status.

Most second-line medicines lack thorough safety data during pregnancy, several require strict birth control during and after treatment, and mycophenolate mofetil is strictly contraindicated during pregnancy, everydayhealth.com stated.

Weill Cornell Medicine, originally founded as Cornell University Medical College in 1898, was established in New York City because the university’s main campus in Ithaca was considered too small to provide sufficient clinical training. The institution has since expanded its reach significantly, including the 2001 opening of a medical school in Qatar.

BTK inhibitors such as rilzabrutinib (Wayrilz) block Bruton’s tyrosine kinase, reducing B-cell antibody production and macrophage platelet destruction with side effects mirroring other targeted therapies. As new therapeutic options emerge, balancing efficacy against long-term safety profiles remains the cornerstone of managing chronic immune thrombocytopenia in clinical practice.

Photo of author

Health Desk

Health Desk at Archyde.

Mississippi Pediatricians Urge Vaccine Review After US Loses Measles Status